BioAtla (BCAB) Projected to Release Earnings on Thursday

BioAtla (NASDAQ:BCAB) is expected to be announcing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

BioAtla Price Performance

Shares of NASDAQ:BCAB opened at $0.16 on Thursday. The business has a fifty day moving average price of $0.23 and a 200-day moving average price of $0.56. The company has a market capitalization of $10.15 million, a PE ratio of -0.14 and a beta of 1.08. BioAtla has a 1-year low of $0.13 and a 1-year high of $1.43.

Wall Street Analysts Forecast Growth

Several analysts recently commented on BCAB shares. Rodman & Renshaw initiated coverage on shares of BioAtla in a research report on Tuesday, January 13th. They set a “buy” rating and a $4.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAtla in a report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BioAtla has a consensus rating of “Hold” and a consensus target price of $4.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BCAB. Woodline Partners LP purchased a new stake in shares of BioAtla during the first quarter valued at $26,000. ADAR1 Capital Management LLC bought a new stake in BioAtla in the 4th quarter worth about $104,000. Susquehanna International Group LLP raised its position in BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after buying an additional 177,760 shares during the last quarter. Jane Street Group LLC raised its position in BioAtla by 55.4% in the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after buying an additional 123,597 shares during the last quarter. Finally, Millennium Management LLC bought a new position in BioAtla during the 3rd quarter valued at about $235,000. 77.23% of the stock is owned by institutional investors.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.